Parabilis Medicines IPO; FDA Names New Interim Chief
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Parabilis Medicines filed to go public under the ticker PBLS.
- David Kessler said he has great confidence in interim FDA chief Kyle Diamantas.
- Kyle Diamantas became the interim FDA chief after Marty Makary left the agency.
Why it matters: Investors gain a new biotech ticker (PBLS) to trade, while Parabilis Medicines can tap public capital to fund its pipeline, and the FDA’s confident interim chief may smooth drug approvals.
Ask SkimNews
